HIV Care Access
Merck Partners with ADAP Task Force to Expand Access to New HIV Treatment
Anonymous
Merck has struck a deal with the ADAP Crisis Task Force to bring its newly approved HIV drug, IDVYNSO™ (doravirine/islatravir), to state AIDS Drug Assistance Programs across the country, Business Wire reported. The agreement means roughly 312,000 low-income and uninsured Americans who rely on these programs can now access the once-daily pill, which the FDA approved on April 14, 2026.
IDVYNSO combines two antiviral agents into a single tablet taken once a day. It is approved for adults who are already virologically suppressed — meaning their HIV levels are below 50 copies per milliliter of blood. Merck's list price before the ACTF deal was an estimated $3,400 per month, according to Financial Content.
A Drug That Nearly Failed Before It Launched
The road to approval was not smooth. In late 2021, Merck paused clinical trials for islatravir — the key molecule in IDVYNSO — after patients showed drops in T-cell counts, the immune cells HIV already attacks. Higher doses were causing the very harm the drug was meant to prevent.
Merck restructured the trials around a much lower dose: 0.25 mg of islatravir paired with 100 mg of doravirine. The gamble paid off. Phase 3 trial data showed 95% of patients stayed virally suppressed through 48 weeks. Merck submitted the drug for FDA approval in November 2025 and received the green light less than five months later.
ACTF Deal Shields State Budgets From Drug's High Sticker Price
State AIDS Drug Assistance Programs, known as ADAPs, serve about 25% of all people living with HIV in the United States. Without a rebate deal, adding a $3,400-per-month drug to their formularies could have forced states like Florida and Texas — which carry heavy HIV burdens — to cut services or create waiting lists.
The ACTF, which has acted as a collective bargaining body for state programs since 2002, reached a final agreement with Merck on June 23, 2026. The specific rebate is confidential, but historical ACTF discounts on new HIV drugs have ranged from 25% to 50% off the list price. ACTF Chair Stephen Weiss said the deal ensures IDVYNSO is available "at a price point that doesn't force states to choose between new treatments and maintaining their current patient rolls."
Merck Locks In Market Share Against Gilead and ViiV
Analysts see the ACTF agreement as a smart volume play. By accepting lower per-pill margins through rebates, Merck secures guaranteed access to the public-payer market — putting direct pressure on rivals Gilead Sciences, maker of Biktarvy, and ViiV Healthcare, maker of Dovato. Losing ADAP formulary spots to a new competitor would be a serious blow for either company.
Not everyone is cheering. Consumer watchdog groups have raised concerns that rebate deals can lock states into one drug and crowd out cheaper alternatives. The Fair Pricing Coalition welcomed the access agreement but called for transparency on the net price after rebates, arguing that HIV drug list prices remain an "unsustainable burden" on the healthcare system.
Patient Support Program Covers Co-Pays and Insurance Navigation
Alongside the ACTF deal, Merck launched the Merck Access Program to help individual patients who get IDVYNSO outside of ADAP. The program offers insurance benefits checks, estimates of out-of-pocket costs, and co-pay assistance for eligible patients. Dr. Eliav Barr, Chief Medical Officer at Merck Research Laboratories, said the goal is to ensure "innovation is not just a laboratory success, but a clinical reality" for those who depend on these programs.
The FDA will continue to monitor IDVYNSO through post-marketing surveillance, focusing on long-term lymphocyte and CD4+ T-cell counts — the same safety signal that paused the trials in 2021. How that data develops will shape the drug's future on both ADAP formularies and private insurance plans.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
4
Articles
3
Reach
4
A
AnonymousAuthor
